A fluorescent ESIPT-based benzimidazole platform for the ratiometric two-photon imaging of ONOO − in vitro and ex vivo

In this work, we have developed an ESIPT-based benzimidazole platform ( MO-E1 and MO-E2 ) for the two-photon cell imaging of ONOO − and a potential ONOO − -activated theranostic scaffold ( MO-E3 ). Each benzimidazole platform, MO-E1–3 , were shown to rapidly detect ONOO − at micromolar concentration...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemical science (Cambridge) 2020-07, Vol.11 (28), p.7329-7334
Hauptverfasser: Odyniec, Maria L., Park, Sang-Jun, Gardiner, Jordan E., Webb, Emily C., Sedgwick, Adam C., Yoon, Juyoung, Bull, Steven D., Kim, Hwan Myung, James, Tony D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this work, we have developed an ESIPT-based benzimidazole platform ( MO-E1 and MO-E2 ) for the two-photon cell imaging of ONOO − and a potential ONOO − -activated theranostic scaffold ( MO-E3 ). Each benzimidazole platform, MO-E1–3 , were shown to rapidly detect ONOO − at micromolar concentrations (LoD = 0.28 μM, 6.53 μM and 0.81 μM respectively). The potential theranostic MO-E3 was shown to release the parent fluorophore and drug indomethacin in the presence of ONOO − but unfortunately did not perform well in vitro due to low solubility. Despite this, the parent scaffold MO-E2 demonstrated its effectiveness as a two-photon imaging tool for the ratiometric detection of endogenous ONOO − in RAW264.7 macrophages and rat hippocampus tissue. These results demonstrate the utility of this ESIPT benzimidazole-based platform for theranostic development and bioimaging applications.
ISSN:2041-6520
2041-6539
DOI:10.1039/d0sc02347g